Table 1.
Baseline demographic and clinical features
| Efficacy Analysis Set | MMSE 21 to 24 | MMSE ≥ 25 | Any Cognitive‐Enhancing Medication | Any Acetylcholinesterase Inhibitor | Memantine | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PIM | Placebo | PIM | Placebo | PIM | Placebo | PIM | Placebo | PIM | Placebo | PIM | Placebo | |
| Demographics | (N = 95) | (N = 90) | (n = 29) | (n = 21) | (n = 66) | (n = 69) | (N = 33) | (N = 36) | (N = 31) | (N = 32) | (N = 6) | (N = 12) |
| Age (years) | 72.4 (6.6) | 72.4 (7.9) | 73.4 (6.4) | 72.5 (9.1) | 72.0 (6.6) | 72.3 (7.6) | 73.1 (6.10) | 72.9 (8.4) | 72.9 (6.0) | 74.1 (7.9) | 73.2 (9.2) | 72.5 (9.2) |
| Sex (%), male | 64 (67.4) | 52 (57.8) | 18 (62.1) | 16 (76.2) | 46 (69.7) | 36 (52.2) | 21 (63.6) | 27 (75.0) | 20 (64.5) | 25 (78.1) | 3 (50.0) | 10 (83.3) |
| PD duration (years) | 9.7 (6.5) | 10.6 (6.7) | 11.1 (6.9) | 12.0 (7.2) | 9.0 (6.3) | 10.2 (6.5) | 10.7 (7.7) | 8.4 (5.0) | 11.0 (7.8) | 8.9 (5.0) | 9.8 (7.3) | 9.0 (4.1) |
| PDP duration (months) | 30.9 (30.0) | 36.4 (39.6) | 30.8 (36.1) | 34.2 (21.8) | 30.9 (27.3) | 37.1 (43.7) | 37.8 (36.0) | 32.6 (26.8) | 39.7 (36.3) | 33.1 (27.6) | 29.2 (21.6) | 31.3 (17.0) |
| SAPS‐PD | 15.9 (6.1) | 14.7 (5.6) | 16.9 (6.0) | 14.2 (5.1) | 15.5 (6.2) | 14.9 (5.7) | 16.8 (6.5) | 14.6 (5.9) | 16.8 (6.6) | 15.1 (5.9) | 18.0 (6.3) | 12.1 (2.8) |
| CGI severity | 4.3 (0.9) | 4.3 (0.9) | 4.5 (0.9) | 4.8 (0.8) | 4.2 (0.9) | 4.2 (0.9) | 4.0 (0.8) | 4.5 (0.9) | 4.0 (0.8) | 4.6 (1.0) | 4.2 (0.8) | 4.5 (1.0) |
| MMSE | 26.0 (2.6) | 26.6 (2.4) | 22.8 (1.1) | 23.1 (1.1) | 27.4 (1.6) | 27.6 (1.5) | 25.9 (2.4) | 26.1 (2.6) | 26.0 (2.5) | 25.9 (2.7) | 25.2 (1.9) | 26.4 (2.35) |
Mean (SD).